FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1565-1571 November 18, 1999 Number 21 Next

Abstract Full Text PDF Editorial by Raje, N. Letters Letters Add to Personal Archive Add to Citation Manager E-mail When Cited Related Article PubMed Citation

From the Myeloma and Lymphoma Program, South Carolina Cancer Center, University of South Carolina, Columbia (S.S., J.M.); the Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock (R.D., D.A., P.R., P.E., N.M., E.A., C.W., J.Z., B.B.); and the Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York (M.D.). Other authors were David Siegel, M.D., Ph.D., University of Arkansas for Medical Sciences, Little Rock, and John Crowley, Ph.D., Fred Hutchinson Cancer Research Center, Seattle.

Address reprint requests to Dr. Barlogie at the Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 623, Little Rock, AR 72205.

Full Text of this Article

Related Letters:

Thalidomide in Multiple Myeloma
Kishi Y., Oki Y., Machida U., Barlogie B.
Extract | Full Text  
N Engl J Med 2000; 342:975-976, Mar 30, 2000. Correspondence

Life-Threatening Toxic Epidermal Necrolysis with Thalidomide Therapy for Myeloma
Rajkumar S. V., Gertz M. A., Witzig T. E.
Extract | Full Text  
N Engl J Med 2000; 343:972-973, Sep 28, 2000. Correspondence

This article has been cited by other articles:

• Cavo, M., Di Raimondo, F., Zamagni, E., Patriarca, F., Tacchetti, P., Casulli, A. F., Volpe, S., Perrone, G., Ledda, A., Ceccolini, M., Califano, C., Bigazzi, C., Offidani, M., Stefani, P., Ballerini, F., Fiacchini, M., de Vivo, A., Brioli, A., Tosi, P., Baccarani, M. (2009). Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma. JCO 27: 5001-5007 [Abstract] [Full Text]  
• Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., Kyle, R. A., Fonseca, R., Bergsagel, P. L., Roy, V., Mikhael, J. R., Stewart, A. K., Laumann, K., Allred, J. B., Mandrekar, S. J., Rajkumar, S. V. (2009). Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. JCO 27: 5008-5014 [Abstract] [Full Text]  
• Falanga, A., Marchetti, M. (2009). Venous Thromboembolism in the Hematologic Malignancies. JCO 27: 4848-4857 [Abstract] [Full Text]  
• Lee, S. M., Woll, P. J., Rudd, R., Ferry, D., O'Brien, M., Middleton, G., Spiro, S., James, L., Ali, K., Jitlal, M., Hackshaw, A. (2009). Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. JNCI J Natl Cancer Inst 101: 1049-1057 [Abstract] [Full Text]  
• Hulin, C., Facon, T., Rodon, P., Pegourie, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J.-P., Lenain, P., Casassus, P., Azais, I., Decaux, O., Garderet, L., Mathiot, C., Fontan, J., Lafon, I., Virion, J. M., Moreau, P. (2009). Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial. JCO 27: 3664-3670 [Abstract] [Full Text]  
• Varettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C., Lazzarino, M. (2009). Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 0: mdp329v1-mdp329 [Abstract] [Full Text]  
• Dahut, W. L., Aragon-Ching, J. B., Woo, S., Tohnya, T. M., Gulley, J. L., Arlen, P. M., Wright, J. J., Ventiz, J., Figg, W. D. (2009). Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer. J Clin Pharmacol 49: 650-660 [Abstract] [Full Text]  
• Harousseau, J.-L., Dreyling, M., On behalf of the ESMO Guidelines Working Group, (2009). Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv97-iv99 [Full Text]  
• Knop, S., Gerecke, C., Liebisch, P., Topp, M. S., Platzbecker, U., Sezer, O., Vollmuth, C., Falk, K., Glasmacher, A., Maeder, U., Einsele, H., Bargou, R. C. (2009). Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113: 4137-4143 [Abstract] [Full Text]  
• Ocio, E. M., Maiso, P., Chen, X., Garayoa, M., Alvarez-Fernandez, S., San-Segundo, L., Vilanova, D., Lopez-Corral, L., Montero, J. C., Hernandez-Iglesias, T., de Alava, E., Galmarini, C., Aviles, P., Cuevas, C., San-Miguel, J. F., Pandiella, A. (2009). Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 113: 3781-3791 [Abstract] [Full Text]  
• Ludwig, H., Hajek, R., Tothova, E., Drach, J., Adam, Z., Labar, B., Egyed, M., Spicka, I., Gisslinger, H., Greil, R., Kuhn, I., Zojer, N., Hinke, A. (2009). Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113: 3435-3442 [Abstract] [Full Text]  
• Brenner, H., Gondos, A., Pulte, D. (2009). Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. haematol 94: 270-275 [Abstract] [Full Text]  
• Baumann, P., Mandl-Weber, S., Volkl, A., Adam, C., Bumeder, I., Oduncu, F., Schmidmaier, R. (2009). Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Molecular Cancer Therapeutics 8: 366-375 [Abstract] [Full Text]  
• Saad, A. A, Sharma, M., Higa, G. M (2009). Treatment of Multiple Myeloma in the Targeted Therapy Era. The Annals of Pharmacotherapy 43: 329-338 [Abstract] [Full Text]  
• Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A., Callea, V., Montanaro, M., Ria, R., Capaldi, A., Zambello, R., Benevolo, G., Derudas, D., Dore, F., Cavallo, F., Gay, F., Falco, P., Ciccone, G., Musto, P., Cavo, M., Boccadoro, M. (2008). Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112: 3107-3114 [Abstract] [Full Text]  
• Barlogie, B., van Rhee, F., Shaughnessy, J. D. Jr, Epstein, J., Yaccoby, S., Pineda-Roman, M., Hollmig, K., Alsayed, Y., Hoering, A., Szymonifka, J., Anaissie, E., Petty, N., Kumar, N. S., Srivastava, G., Jenkins, B., Crowley, J., Zeldis, J. B. (2008). Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 112: 3122-3125 [Abstract] [Full Text]  
• Reece, D. E., Rodriguez, G. P., Chen, C., Trudel, S., Kukreti, V., Mikhael, J., Pantoja, M., Xu, W., Stewart, A. K. (2008). Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma. JCO 26: 4777-4783 [Abstract] [Full Text]  
• Durie, B. G.M. (2008). Myeloma Therapy: 25 Years Forward--Immune Modulation Then and Now. JCO 26: 4698-4700 [Full Text]  
• Lafaras, C., Mandala, E., Verrou, E., Platogiannis, D., Barbetakis, N., Bischiniotis, T., Zervas, K. (2008). Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study. Ann Oncol 19: 1765-1769 [Abstract] [Full Text]  
• Rajkumar, S. V. (2008). Treatment of Myeloma: Cure vs Control. Mayo Clin Proc. 83: 1142-1145 [Full Text]  
• van Rhee, F., Dhodapkar, M., Shaughnessy, J. D. Jr, Anaissie, E., Siegel, D., Hoering, A., Zeldis, J., Jenkins, B., Singhal, S., Mehta, J., Crowley, J., Jagannath, S., Barlogie, B. (2008). First thalidomide clinical trial in multiple myeloma: a decade. Blood 112: 1035-1038 [Abstract] [Full Text]  
• Mei, S.-C., Wu, R.-T. (2008). The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. Molecular Cancer Therapeutics 7: 2405-2414 [Abstract] [Full Text]  
• Palumbo, A., Gay, F., Bringhen, S., Falcone, A., Pescosta, N., Callea, V., Caravita, T., Morabito, F., Magarotto, V., Ruggeri, M., Avonto, I., Musto, P., Cascavilla, N., Bruno, B., Boccadoro, M. (2008). Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 19: 1160-1165 [Abstract] [Full Text]  
• Khong, T., Sharkey, J., Spencer, A. (2008). The effect of azacitidine on interleukin-6 signaling and nuclear factor-{kappa}B activation and its in vitro and in vivo activity against multiple myeloma. haematol 93: 860-869 [Abstract] [Full Text]  
• Rajkumar, S. V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., Blade, J. (2008). Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. JCO 26: 2171-2177 [Abstract] [Full Text]  
• Palumbo, A., Facon, T., Sonneveld, P., Blade, J., Offidani, M., Gay, F., Moreau, P., Waage, A., Spencer, A., Ludwig, H., Boccadoro, M., Harousseau, J.-L. (2008). Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111: 3968-3977 [Abstract] [Full Text]  
• Chanan-Khan, A. A., Cheson, B. D. (2008). Lenalidomide for the Treatment of B-Cell Malignancies. JCO 26: 1544-1552 [Abstract] [Full Text]  
• Kyle, R. A., Rajkumar, S. V. (2008). Multiple myeloma. Blood 111: 2962-2972 [Abstract] [Full Text]  
• Hwang, S. H., Rait, A., Pirollo, K. F., Zhou, Q., Yenugonda, V. M., Chinigo, G. M., Brown, M. L., Chang, E. H. (2008). Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Molecular Cancer Therapeutics 7: 559-568 [Abstract] [Full Text]  
• Brenner, H., Gondos, A., Pulte, D. (2008). Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111: 2521-2526 [Abstract] [Full Text]  
• Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., Greipp, P. R., Kyle, R. A., Gertz, M. A. (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520 [Abstract] [Full Text]  
• Abdelkefi, A., Ladeb, S., Torjman, L., Othman, T. B., Lakhal, A., Romdhane, N. B., Omri, H. E., Elloumi, M., Belaaj, H., Jeddi, R., Aissaoui, L., Ksouri, H., Hassen, A. B., Msadek, F., Saad, A., Hsairi, M., Boukef, K., Amouri, A., Louzir, H., Dellagi, K., Abdeladhim, A. B., on behalf of the Tunisian Multiple Myeloma Study G, (2008). Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111: 1805-1810 [Abstract] [Full Text]  
• Bensinger, W. (2008). Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs. JCO 26: 480-492 [Abstract] [Full Text]  
• Matsui, W., Wang, Q., Barber, J. P., Brennan, S., Smith, B. D., Borrello, I., McNiece, I., Lin, L., Ambinder, R. F., Peacock, C., Watkins, D. N., Huff, C. A., Jones, R. J. (2008). Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance. Cancer Res. 68: 190-197 [Abstract] [Full Text]  
• Johnson, B. E., Rudin, C. M., Salgia, R. (2008). Novel and Targeted Agents for Small Cell Lung Cancer. Am Soc Clin Oncol Ed Book 2008: 363-367 [Abstract] [Full Text]  
• Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., Knight, R. D., the Multiple Myeloma (010) Study Investigators, (2007). Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. NEJM 357: 2123-2132 [Abstract] [Full Text]  
• Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J. B., Knight, R. D., the Multiple Myeloma (009) Study Investigators, (2007). Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. NEJM 357: 2133-2142 [Abstract] [Full Text]  
• Dimopoulos, M. A., Souliotis, V. L., Anagnostopoulos, A., Bamia, C., Pouli, A., Baltadakis, I., Terpos, E., Kyrtopoulos, S. A., Sfikakis, P. P. (2007). Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. haematol 92: 1505-1512 [Abstract] [Full Text]  
• Rajkumar, S. V., Richardson, P. G., Lacy, M. Q., Dispenzieri, A., Greipp, P. R., Witzig, T. E., Schlossman, R., Sidor, C. F., Anderson, K. C., Gertz, M. A. (2007). Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma. Clin. Cancer Res. 13: 6162-6167 [Abstract] [Full Text]  
• Aerbajinai, W., Zhu, J., Gao, Z., Chin, K., Rodgers, G. P. (2007). Thalidomide induces {gamma}-globin gene expression through increased reactive oxygen species mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 110: 2864-2871 [Abstract] [Full Text]  
• Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., Ciccone, G., Omede, P., Ambrosini, M. T., Gay, F., Bringhen, S., Musto, P., Foa, R., Knight, R., Zeldis, J. B., Boccadoro, M., Petrucci, M. T. (2007). Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network. JCO 25: 4459-4465 [Abstract] [Full Text]  
• Pujol, J. L., Breton, J. L., Gervais, R., Tanguy, M.-L., Quoix, E., David, P., Janicot, H., Westeel, V., Gameroff, S., Geneve, J., Maraninchi, D. (2007). Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04 IFCT 00-01. JCO 25: 3945-3951 [Abstract] [Full Text]  
• Rao, K. V. (2007). Lenalidomide in the treatment of multiple myeloma. Am J Health Syst Pharm 64: 1799-1807 [Abstract] [Full Text]  
• Yildirim, N. D., Ayer, M., Kucukkaya, R. D., Alpay, N., Mete, O., Yenerel, M. N., Yavuz, A. S., Nalcaci, M. (2007). Leukocytoclastic Vasculitis due to Thalidomide in Multiple Myeloma. Jpn J Clin Oncol 37: 704-707 [Abstract] [Full Text]  
• Katzel, J. A., Hari, P., Vesole, D. H. (2007). Multiple Myeloma: Charging Toward a Bright Future. CA Cancer J Clin 57: 301-318 [Abstract] [Full Text]  
• Li, Y., Hou, J., Jiang, H., Wang, D., Fu, W., Yuan, Z., Chen, Y., Zhou, L. (2007). Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma. haematol 92: 1246-1249 [Abstract] [Full Text]  
• Plasmati, R., Pastorelli, F., Cavo, M., Petracci, E., Zamagni, E., Tosi, P., Cangini, D., Tacchetti, P., Salvi, F., Bartolomei, I., Michelucci, R., Tassinari, C. A. (2007). Neuropathy in multiple myeloma treated with thalidomide: A prospective study. Neurology 69: 573-581 [Abstract] [Full Text]  
• Zervas, K, Mihou, D, Katodritou, E, Pouli, A, Mitsouli, C., Anagnostopoulos, A, Delibasi, S, Kyrtsonis, M., Anagnostopoulos, N, Terpos, E, Zikos, P, Maniatis, A, Dimopoulos, M., On behalf of the Greek Myeloma Study Group, (2007). VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. Ann Oncol 18: 1369-1375 [Abstract] [Full Text]  
• Sirohi, B, Powles, R, Lawrence, D, Treleaven, J, Kulkarni, S, Leary, A, Rudin, C, Horton, C, Morgan, G (2007). An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-{alpha}2b in patients with multiple myeloma maintained on a steady dose of interferon-{alpha}2b. Ann Oncol 18: 1388-1394 [Abstract] [Full Text]  
• Mileshkin, L., Honemann, D., Gambell, P., Trivett, M., Hayakawa, Y., Smyth, M., Beshay, V., Ritchie, D., Simmons, P., Milner, A. D., Zeldis, J. B., Prince, H. M. (2007). Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. haematol 92: 1075-1082 [Abstract] [Full Text]  
• Sonneveld, P., van der Holt, B., Segeren, C. M., Vellenga, E., Croockewit, A. J., Verhoef, G. E.G., Cornelissen, J. J., Schaafsma, M. R., van Oers, M. H.J., Wijermans, P. W., Westveer, P. H.M., Lokhorst, H. M. (2007). Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. haematol 92: 928-935 [Abstract] [Full Text]  
• Tabata, C., Tabata, R., Kadokawa, Y., Hisamori, S., Takahashi, M., Mishima, M., Nakano, T., Kubo, H. (2007). Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice. J. Immunol. 179: 708-714 [Abstract] [Full Text]  
• Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de Vivo, A., Gozzetti, A., Lazzaro, A., Tura, S., Baccarani, M. (2007). Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. JCO 25: 2434-2441 [Abstract] [Full Text]  
• Richardson, P. G., Mitsiades, C., Schlossman, R., Munshi, N., Anderson, K. (2007). New Drugs for Myeloma. The Oncologist 12: 664-689 [Abstract] [Full Text]  
• Kristinsson, S. Y., Landgren, O., Dickman, P. W., Derolf, A. R., Bjorkholm, M. (2007). Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003. JCO 25: 1993-1999 [Abstract] [Full Text]  
• Carlo-Stella, C., Guidetti, A., Di Nicola, M., Lavazza, C., Cleris, L., Sia, D., Longoni, P., Milanesi, M., Magni, M., Nagy, Z., Corradini, P., Carbone, A., Formelli, F., Gianni, A. M. (2007). IFN-{gamma} Enhances the Antimyeloma Activity of the Fully Human Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. Cancer Res. 67: 3269-3275 [Abstract] [Full Text]  
• Richardson, P. (2007). Toward a new therapeutic backbone in myeloma. Blood 109: 2672-2673 [Full Text]  
• Palumbo, A., Ambrosini, M. T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., Bringhen, S., Falco, P., Avonto, I., Cavallo, F., Boccadoro, M., for the Italian Multiple Myeloma Network, Gruppo I, (2007). Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109: 2767-2772 [Abstract] [Full Text]  
• Fonseca, R., Stewart, A. K. (2007). Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. Molecular Cancer Therapeutics 6: 802-810 [Abstract] [Full Text]  
• Armand, J.-P., Burnett, A. K., Drach, J., Harousseau, J.-L., Lowenberg, B., San Miguel, J. (2007). The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib. The Oncologist 12: 281-290 [Abstract] [Full Text]  
• Sekimoto, E., Ozaki, S., Ohshima, T., Shibata, H., Hashimoto, T., Abe, M., Kimura, N., Hattori, K., Kawai, S., Kinoshita, Y., Yamada-Okabe, H., Tsuchiya, M., Matsumoto, T. (2007). A Single-Chain Fv Diabody against Human Leukocyte Antigen-A Molecules Specifically Induces Myeloma Cell Death in the Bone Marrow Environment. Cancer Res. 67: 1184-1192 [Abstract] [Full Text]  
• Sanchorawala, V., Wright, D. G., Rosenzweig, M., Finn, K. T., Fennessey, S., Zeldis, J. B., Skinner, M., Seldin, D. C. (2007). Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 109: 492-496 [Abstract] [Full Text]  
• Richardson, P. G., Hideshima, T., Anderson, K. C. (2007). Plasma cell dyscrasias. ASH-SAP 2007: 298-327 [Full Text]  
• Baz, R, Walker, E, Karam, M., Choueiri, T., Jawde, R., Bruening, K, Reed, J, Faiman, B, Ellis, Y, Brand, C, Srkalovic, G, Andresen, S, Knight, R, Zeldis, J, Hussein, M. (2006). Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17: 1766-1771 [Abstract] [Full Text]  
• Lin, Y.-C., Shun, C.-T., Wu, M.-S., Chen, C.-C. (2006). A Novel Anticancer Effect of Thalidomide: Inhibition of Intercellular Adhesion Molecule-1-Mediated Cell Invasion and Metastasis through Suppression of Nuclear Factor-{kappa}B. Clin. Cancer Res. 12: 7165-7173 [Abstract] [Full Text]  
• Lonial, S. (2006). When "the same" is really "different". Blood 108: 3233-3234 [Full Text]  
• Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., Munshi, N. C., Kelly-Colson, K., Doss, D., McKenney, M. L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W. S., Zeldis, J., Knight, R., Weller, E., Anderson, K. C. (2006). A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108: 3458-3464 [Abstract] [Full Text]  
• Attal, M., Harousseau, J.-L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I. Y., Bourhis, J.-H., Garderet, L., Pegourie, B., Dumontet, C., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Caillot, D., Grobois, B., Avet-Loiseau, H., Moreau, P., Facon, T., for the Inter-Groupe Francophone du Myelome (IFM), (2006). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108: 3289-3294 [Abstract] [Full Text]  
• Singhal, S., Mehta, J. (2006). Multiple Myeloma. CJASN 1: 1322-1330 [Abstract] [Full Text]  
• Barlogie, B., Tricot, G. (2006). Complete response in myeloma: a Trojan horse?. Blood 108: 2134-2134 [Full Text]  
• Chang, D. H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S. D., Jagannath, S., Dhodapkar, M. V. (2006). Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108: 618-621 [Abstract] [Full Text]  
• Eom, K.-S., Min, C.-K., Lee, S., Kim, Y.-J., Kim, S.-Y., Kim, H.-J., Lee, J.-W., Min, W.-S., Kim, C.-C. (2006). Efficacy of Up-Front Treatment with a Double Stem Cell Transplantation in Multiple Myeloma. Jpn J Clin Oncol 36: 432-438 [Abstract] [Full Text]  
• Richardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D. S., Irwin, D., Schuster, M., Srkalovic, G., Alexanian, R., Rajkumar, S. V., Limentani, S., Alsina, M., Orlowski, R. Z., Najarian, K., Esseltine, D., Anderson, K. C., Amato, A. A. (2006). Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. JCO 24: 3113-3120 [Abstract] [Full Text]  
• Lacy, M. Q. (2006). Multiple Myeloma: New Options, New Challenges. Mayo Clin Proc. 81: 877-879 [Full Text]  
• Hussein, M. A., Baz, R., Srkalovic, G., Agrawal, N., Suppiah, R., Hsi, E., Andresen, S., Karam, M. A., Reed, J., Faiman, B., Kelly, M., Walker, E. (2006). Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma. Mayo Clin Proc. 81: 889-895 [Abstract] [Full Text]  
• Anderson, G., Gries, M., Kurihara, N., Honjo, T., Anderson, J., Donnenberg, V., Donnenberg, A., Ghobrial, I., Mapara, M. Y., Stirling, D., Roodman, D., Lentzsch, S. (2006). Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107: 3098-3105 [Abstract] [Full Text]  
• Barlogie, B., Tricot, G., Rasmussen, E., Anaissie, E., van Rhee, F., Zangari, M., Fassas, A., Hollmig, K., Pineda-Roman, M., Shaughnessy, J., Epstein, J., Crowley, J. (2006). Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107: 2633-2638 [Abstract] [Full Text]  
• Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M., Crowley, J. (2006). Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. NEJM 354: 1021-1030 [Abstract] [Full Text]  
• Vessella, R. L., Guise, T. A., Susman, E. S., Suva, L. J., Clines, G. A., Kominsky, S. L., Weber, K. L., Chirgwin, J. M., McCauley, L. K., Kozlow, W. (2006). Meeting Report from Skeletal Complications of Malignancy IV: A symposium jointly sponsored by The Paget Foundation for Paget's Disease of Bone and Related Disorders, the National Cancer Institute, and the University of Virginia School of Medicine * April 28-30, 2005 in Bethesda, Maryland, USA. IBMS BoneKEy 3: 15-42 [Full Text]  
• Haubitz, M., Peest, D. (2006). Myeloma - new approaches to combined nephrological-haematological management. Nephrol Dial Transplant 21: 582-590 [Full Text]  
• Lee, C. P., Patel, P. M., Selby, P. J., Hancock, B. W., Mak, I., Pyle, L., James, M. G., Beirne, D. A., Steeds, S., A'Hern, R., Gore, M. E., Eisen, T. (2006). Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma. JCO 24: 898-903 [Abstract] [Full Text]  
• Hsu, W.-C., Chan, S.-C., Ting, L.-L., Chung, N.-N., Wang, P.-M., Ying, K.-S., Shin, J.-S., Chao, C.-J., Lin, G.-D. (2006). Results of Three-Dimensional Conformal Radiotherapy and Thalidomide for Advanced Hepatocellular Carcinoma. Jpn J Clin Oncol 36: 93-99 [Abstract] [Full Text]  
• Li, P.-K., Pandit, B., Sackett, D. L., Hu, Z., Zink, J., Zhi, J., Freeman, D., Robey, R. W., Werbovetz, K., Lewis, A., Li, C. (2006). A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities.. Molecular Cancer Therapeutics 5: 450-456 [Abstract] [Full Text]  
• Colleoni, M., Orlando, L., Sanna, G., Rocca, A., Maisonneuve, P., Peruzzotti, G., Ghisini, R., Sandri, M. T., Zorzino, L., Nole, F., Viale, G., Goldhirsch, A. (2006). Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17: 232-238 [Abstract] [Full Text]  
• Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., Greipp, P. R. (2006). Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. JCO 24: 431-436 [Abstract] [Full Text]  
• Richardson, P., Anderson, K. (2006). Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma. JCO 24: 334-336 [Full Text]  
• Roccaro, A. M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., Dammacco, F., Richardson, P. G., Anderson, K. C. (2006). Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells. Cancer Res. 66: 184-191 [Abstract] [Full Text]  
• Orlowski, R. Z. (2006). Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation. ASH Education Book 2006: 338-347 [Abstract] [Full Text]  
• Zonder, J. A. (2006). Thrombotic Complications of Myeloma Therapy. ASH Education Book 2006: 348-355 [Abstract] [Full Text]  
• Augustson, B. M., Begum, G., Dunn, J. A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., Drayson, M. T. (2005). Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. JCO 23: 9219-9226 [Abstract] [Full Text]  
• David, E., Sun, S.-Y., Waller, E. K., Chen, J., Khuri, F. R., Lonial, S. (2005). The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 106: 4322-4329 [Abstract] [Full Text]  
• Rajkumar, S. V. (2005). Thalidomide Therapy and Deep Venous Thrombosis in Multiple Myeloma. Mayo Clin Proc. 80: 1549-1551  
• Trieu, Y., Trudel, S., Pond, G. R., Mikhael, J., Jaksic, W., Reece, D. E., Chen, C. I., Stewart, A. K. (2005). Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation. Mayo Clin Proc. 80: 1578-1582 [Abstract]  
• Chanan-Khan, A., Miller, K. C., Takeshita, K., Koryzna, A., Donohue, K., Bernstein, Z. P., Mohr, A., Klippenstein, D., Wallace, P., Zeldis, J. B., Berger, C., Czuczman, M. S. (2005). Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 106: 3348-3352 [Abstract] [Full Text]  
• Duyvendak, M., Naunton, M., Kingma, B. J, Brouwers, J. R. (2005). Thalidomide-Associated Thrombocytopenia. The Annals of Pharmacotherapy 39: 1936-1939 [Abstract] [Full Text]